Benign prostatic hyperplasia (BPH) is one of the most common urological diseases among men, which leads to a sharp deterioration in the quality of life, urinary disorders, renal dysfunction, erectile dysfunction. The prevalence of this disease increases with age. Thus, the first clinical manifestations of BPH are present in 25% of men at the age of 40 [9] .
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The task of the prostatic hyperplasia pharmacothe rapy is to reduce the severity of symptoms, to lower the risk of acute urinary retention, and therefore, to reduce the need to perform surgery and improve the overall quality of life of patients [3, 4] .
At present the main therapeutic method for patients with clinical manifestations of BPH is the use of α 1 ad renoblockers. Administration of α 1 blockers reduces pa thological symptoms and improves the urinary flow rate due to relaxation of smooth muscles of the prostate and the bladder neck. Tamsulosin hydrochloride is a selective and competitive blocker of postsynaptic α 1А adrenergic recep tors located in the smooth muscles of the prostate, the bladder neck and the prostatic part of the urethra. Due to the high selectivity to α 1А adrenergic receptors Tam sulosin has no effect on blood pressure of patients [1, 2] .
Today, the most appropriate dosage form for the treat ment of prostate hyperplasia is a suppository. At the phar maceutical market there are no medicines with α-blockers in the form of suppositories, so their development and research is an important and promising direction for the modern pharmaceutical science.
For the further drug quality assurance it is necessary to develop analytical approaches that will ensure com prehensive monitoring for compliance with the existing requirements. Development of the method for the quan titative determination of active pharmaceutical ingredi ents (API) in a drug is an important and necessary step when preparing the Quality Control Methods project. For the Tamsulosin assay different authors proposed spectrophotometric [8, 10] and chromatographic [5, 6, 7] methods. Considering the complex matrix of the me dicine it was necessary to identify and work out the most appropriate method to use.
The aim of the work was to develop the method for quantitative determination of the active substance Tam sulosin hydrochloride in "Tamsuloprost" suppositories for the treatment of prostatic hyperplasia.
Materials and Methods
The objects of the study were samples of supposito ries with the active substance Tamsulosin hydrochlori de with the weight of 1.6 g made of a solid fat by mould ing. In order to optimize the composition of suppositories a Lanette SX emulsifier in the amount of 5% was intro duced into the base.
Development of the assay method was performed on a Specord 200 spectrophotometer (Analytik Jena, Germany) and a ProStar analytical chromatograph (Va rian, USA) using Waters XTerra TM MS C8 columns with 50 mm in length, the diameter of 4.6 mm and the particle size of 2.5 microns with a precolumn.
In the work the following samples of the components of placebo and substances were used: Tamsulosin hy drochloride (Ra Chem Pharma Ltd, s. TAM/021/11/10); Lanette SX emulsifier (Cognis, Germany), solid fat ("Sa sol", Germany).
Results and Discussion
To determine the possibility of using the spectro photometric method in the UVregion compared to the standard solution or by the absorption specific indicator to monitor the content of Tamsulosin hydrochloride in the medicine, the molecular absorption spectra of solu tions of Tamsulosin, the suppository base, placebo and the emulsifier were obtained.
As it can be seen from the spectrum (Fig. 1) for Tamsulosin hydrochloride, the analytical wavelength of either 225 nm or 280 nm can be used. However, both analytical wavelengths are covered by peaks of the placebo component, namely of the emulsifier Lanette-SX, proven during the sample preparation, i.e. it is extracted together with Tamsulosin. Fig. 2a shows the spectra of Tamsulosin hydrochloride and the emulsifier in concentrations of about 0.015 mg/ml and 2.8 mg/ml, respectively (the ratio is 1:186, in the medicine it is 1:200). Thus, at the wavelength of 225 nm the emulsifier will almost twice overstate the results of the quantitative determination of Tamsulosin. Fig. 2b shows the spectra of Tamsulosin Hydrochloride and the emulsifier in concentrations of about 0.015 mg/ml and 0.28 mg/ml, respectively (the ratio is 1:18). So, at the wavelength of 280 nm the emulsifier will overstate the results of the quantitative determination of Tamsulosin by about 20%.
Thus, the use of the spectrophotometric method in the UVregion to determine Tamsulosin hydrochloride in suppositories is difficult due to the significant optical absorption of placebo components. Therefore, to solve this problem a more specific method has been used, namely high performance liquid chromatography (HPLC), and the conditions under which there is a complete se paration of the placebo components and active ingredi ent within the particular time have been proposed. Since the placebo components and Tamsulosin have signifi cant differences in the chemical structure, a different chromatographic behaviour is expected. Taking this into account even a short chromatographic column sharing ability would be enough for an acceptable separation. The use of a short chromatographic column, in its turn, allows to reduce the analysis time and the solvent con sumption for chromatography.
Determination was performed on a Waters XTerra TM MS C8 column, 2.5 microns, 4.6×50 mm. When deve loping the method the various combinations of the mo bile phase composition and pH medium were tested. Fi nally, the method using phosphoric acid -acetonitrilewater in the ratio of 2:32:68 as a mobile phase was cho sen; it was also used as a solvent for extraction of Tam sulosin from the dosage form. Under these conditions there was separation of the placebo components and Tamsulosin, the last was eluted with the retention time of about 1.5 min (RF was about 2.0). The analysis time did not exceed 5 minutes. The chromatogram of the test solution is shown in Fig. 3 . On the basis of the research conducted the assay me thod for Tamsulosin hydrochloride suppositories "Tam suloprost" was developed.
The tests were performed by the method of liquid chromatography according to the requirements of the SPhU (2.2.29). The solutions were used freshly prepa red and protected from light.
Test solution. Place aproximately 3.2 g of the ho mogenized suppository mass in a 100 ml separation fun nel, dissolve it in 50 ml of hexane, then add 7.5 ml of the mobile phase. Shake the emulsion intensely for 5 mi nutes and leave for 20 minutes for complete separation of the layers. Collect the bottom layer carefully in a 25 ml volumetric flask avoiding contact with the top layer in the flask. Repeat the extraction twice more using 7.5 ml of the mobile phase. Dilute the flask content to the vo lume with the solvent for tests and mix.
Blank solution. Place aproximately 0.080 g (accurate weight) of Tamsulosin hydrochloride in a 100 ml volu metric flask, then add 50 ml of methanol, dissolve, di lute to the volume with the same solvent and mix. Place 2 ml of the solution was obtained in a 50 ml volumetric flask, dilute to the volume with the mobile phase and mix.
Before chromatography the solution was filtered through a nylon membrane filter with a pore size not more than 0.45 microns.
Chromatographic conditions were: -a stainless steel column of 50 mm×4.6 mm filled with octylsilyl silica gel for chromatography, with a particle size of 2.5 microns with a precolumn of 20 mm × 4.6 mm, for example, Waters XTerra TM MS C8 2.5 um 4.6 × 50 mm, or a similar one, for which the requirements of the system suitability test were met;
-the mobile phase rate -1.0 ml/min; -detection: spectrophotometry at the wavelength of 280 nm;
-the column temperature -30°C; -the sample volume: 20 mcl; -the mobile phase: a mixture of phosphoric acidacetonitrile for chromatography -water for chromato graphy in the ratio of 2:32:68 degassed by any conve nient method.
The blank solution was chromatographed for several times. The chromatographic system is considered to be applicable if in the comparison solution chromatogram:
-the efficiency of the chromatographic system cal culated by the Tamsulosin peak is not less than 1000 theoretical plates;
-the peak symmetry of Tamsulosin is not more than 2.0; -the relative standard deviation (RSD) of the Tam sulosin peak area for five chromatograms does not exceed 1.0%.
The test solution was chromatographed at least 3 times.
The content of Tamsulosin hydrochloride (X) in 1 suppository, mg, was calculated using the formula:
where: S 1 -is the average value of Tamsulosin peak areas calculated from the test solution chromatograms; S 0 -is the average value of Tamsulosin peak areas cal culated from the sum blank solution; m 0 -is the stan dard sample weight of Tamsulosin hydrochloride used to prepare the sum blank solution, g; m 1 -is the sample weight of the medicine, g; a -is the average weight of a suppository, g; P -is the Tamsulosin hydrochloride content in the standard sample of Tamsulosin hydro chloride, %.
The content of C 20 H 28 N 2 O 5 S•HCl (Tamsulosin hy drochloride) in 1 suppository should be from 0.36 mg to 0.44 mg.
Notes: Preparation of the mobile phase. Mix 320 ml of acetonitrile for chromatography and 680 ml of water for chromatography, add 2 ml of phosphoric acid. Mix thoroughly and filter through a nylon membrane filter with a pore size not more than 0.45 microns. CONCLUSIONS 1. The quantitative determination of the active sub stance Tamsulosin hydrochloride in "Tamsuloprost" sup positories for the treatment of prostatic hyperplasia has been suggested.
2. It has been proven that it is unreasonable to use the method of spectrophotometry in the UVregion to control the content of Tamsulosin in suppositories because of the overlap of two analytical wavelengths of Tamsu losin by the maxima of placebo components.
3. The possibility to use the HPLC method for assay of Tamsulosin hydrochloride in "Tamsuloprost" suppo sitories has been substantiated.
